106 related articles for article (PubMed ID: 7863814)
1. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients.
Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L
J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814
[TBL] [Abstract][Full Text] [Related]
2. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
[TBL] [Abstract][Full Text] [Related]
3. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.
Scagnolari C; Casato M; Bellomi F; De Pisa F; Turriziani O; Coviello R; Pirro MR; Dianzani F; Antonelli G
Clin Diagn Lab Immunol; 2003 Jan; 10(1):70-7. PubMed ID: 12522042
[TBL] [Abstract][Full Text] [Related]
4. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia.
Casato M; Laganà B; Antonelli G; Dianzani F; Bonomo L
Blood; 1991 Dec; 78(12):3142-7. PubMed ID: 1742481
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
[TBL] [Abstract][Full Text] [Related]
8. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study.
Dammacco F; Sansonno D; Han JH; Shyamala V; Cornacchiulo V; Iacobelli AR; Lauletta G; Rizzi R
Blood; 1994 Nov; 84(10):3336-43. PubMed ID: 7524736
[TBL] [Abstract][Full Text] [Related]
9. Deterioration of mixed cryoglobulinemia during treatment with interferon-alpha-2a.
Bojić I; Lilić D; Radojcić C; Mijusković P
J Gastroenterol; 1994 Jun; 29(3):369-71. PubMed ID: 8061808
[TBL] [Abstract][Full Text] [Related]
10. Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha.
Tefferi A; Grendahl DC
Am J Hematol; 1996 Jul; 52(3):231-3. PubMed ID: 8756097
[TBL] [Abstract][Full Text] [Related]
11. Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia.
von Wussow P; Pralle H; Hochkeppel HK; Jakschies D; Sonnen S; Schmidt H; Müller-Rosenau D; Franke M; Haferlach T; Zwingers T
Blood; 1991 Jul; 78(1):38-43. PubMed ID: 2070058
[TBL] [Abstract][Full Text] [Related]
12. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.
Misiani R; Bellavita P; Fenili D; Vicari O; Marchesi D; Sironi PL; Zilio P; Vernocchi A; Massazza M; Vendramin G
N Engl J Med; 1994 Mar; 330(11):751-6. PubMed ID: 8107741
[TBL] [Abstract][Full Text] [Related]
13. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes.
Brand CM; Leadbeater L; Bellati G; Marotta F; Ideo G
J Interferon Res; 1993 Apr; 13(2):121-5. PubMed ID: 7685368
[TBL] [Abstract][Full Text] [Related]
14. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
Rönnblom LE; Janson ET; Perers A; Oberg KE; Alm GV
Clin Exp Immunol; 1992 Sep; 89(3):330-5. PubMed ID: 1516252
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
[TBL] [Abstract][Full Text] [Related]
16. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
von Wussow P; Jakschies D; Freund M; Deicher H
J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
Prümmer O
Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.
Milella M; Antonelli G; Santantonio T; Currenti M; Monno L; Mariano N; Angarano G; Dianzani F; Pastore G
Liver; 1993 Jun; 13(3):146-50. PubMed ID: 8336526
[TBL] [Abstract][Full Text] [Related]
19. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K
J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163
[TBL] [Abstract][Full Text] [Related]
20. [The influence of interferon alpha neutralizing antibodies on the therapeutic effectiveness in patients with chronic viral hepatitis].
Tong F; Tang Y; Bai J
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Dec; 13(4):345-7. PubMed ID: 12759973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
